BioLife Sciences Inc.
BLFE
$0.0001
$0.000.00%
| 02/28/2022 | 02/28/2021 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 122.80K | 58.30K | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 122.80K | 58.30K | |||
| Operating Income | -122.80K | -58.30K | |||
| Income Before Tax | -132.00K | -67.40K | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -132.00K | -67.40K | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -132.00K | -67.40K | |||
| EBIT | -122.80K | -58.30K | |||
| EBITDA | -- | -- | |||
| EPS Basic | 0.00 | 0.00 | |||
| Normalized Basic EPS | 0.00 | 0.00 | |||
| EPS Diluted | 0.00 | 0.00 | |||
| Normalized Diluted EPS | 0.00 | 0.00 | |||
| Average Basic Shares Outstanding | 57.83M | 54.86M | |||
| Average Diluted Shares Outstanding | 57.83M | 54.86M | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
